Navigation Links
Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Board at the 2008 Annual Meeting
Date:2/15/2008

NEW YORK, Feb. 15 /PRNewswire/ -- Accipiter Life Sciences Fund, LP ("Accipiter Life Sciences"), announced today that it has nominated Gabe Hoffman, David Lohman and Eugene I. Davis for election to the Board of Directors of Penwest Pharmaceuticals Co. (the "Company") (Nasdaq: PPCO) at the Company's 2008 Annual Meeting of Shareholders. The Company has not announced the date of the annual meeting. Accipiter Life Sciences, which, together with its affiliates, beneficially owns 2,168,213 shares, or approximately 9.3% of the outstanding shares, of common stock of the Company, submitted written notice of the nominations to the Company's Corporate Secretary in a letter dated February 15, 2008.

CERTAIN INFORMATION CONCERNING PARTICIPANTS

Accipiter Life Sciences Fund, LP ("Accipiter Life Sciences"), together with the other Participants (as defined below), intend to make a preliminary filing with the Securities and Exchange Commission ("SEC") of a proxy statement and accompanying proxy card to be used to solicit votes for the election of a slate of director nominees at the 2008 annual meeting of shareholders of Penwest Pharmaceuticals Co., a Washington corporation (the "Company").

ACCIPITER LIFE SCIENCES ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT WHEN IT IS AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY STATEMENT WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THE SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.

The participants in the proxy solicitation are anticipated to be Accipiter Life Sciences Fund (Offshore), Ltd., ("ALS Fund Offshore"), Accipiter Life Sciences Fund II, LP, ("ALS Fund II"), Accipiter Life Sciences Fund II (Offshore), Ltd., ("ALS Fund II Offshore"), Accipiter Life Sciences Fund II (QP), LP, ("ALS Fund II QP") (together with Accipiter Life Sciences, ALS Fund Offshore, ALS Fund II, ALS Fund II Offshore, ALS Fund II QP, the "Accipiter Entities"), Accipiter Capital Management, LLC, ("Accipiter Management"), Candens Capital, LLC, ("Candens Capital"), Gabe Hoffman, David Lohman and Eugene I. Davis. As of the date of this filing, Accipiter Life Sciences, ALS Fund II and ALS Fund II QP beneficially owned 555,745, 254,029 and 290,330 shares of Common Stock of the Company, respectively. As the general partner of each of Accipiter Life Sciences, ALS Fund II and ALS Fund II QP, Candens Capital may be deemed to beneficially own the 1,100,104 shares of Common Stock of the Company collectively owned by Accipiter Life Sciences, ALS Fund II and ALS Fund II QP.

As of the date of this filing, ALS Fund Offshore and ALS Fund II Offshore beneficially owned 557,048 and 511,061 shares of Common Stock of the Company, respectively. As the investment manager of each of ALS Fund Offshore and ALS Fund II Offshore, Accipiter Management may be deemed to beneficially own the 1,068,109 shares of Common Stock of the Company collectively owned by ALS Fund Offshore and ALS Fund II Offshore.

As of the date of this filing Mr. Hoffman may be deemed to beneficially own 2,168,213 shares of Common Stock collectively owned by the Accipiter Entities. Mr. Hoffman has sole voting and dispositive power with respect to the 2,168,213 Shares owned by the Accipiter Entities. Each of Candens Capital, Accipiter Management and Gabe Hoffman disclaims beneficial ownership of the shares of Common Stock of the Company owned by the Accipiter Entities except to the extent of its or his pecuniary interest therein. Currently, each of Messrs. Lohman and Davis do not beneficially own any shares of Common Stock of the Company. As members of a "group" for the purposes of Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended, each of Messrs. Lohman and Davis are deemed to beneficially own the 2,168,213 shares of Common Stock owned by the Accipiter Entities.


'/>"/>
SOURCE Accipiter Life Sciences Fund, LP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
2. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
3. Rural/Metro Board of Directors Meets With Accipiter Capital Management
4. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
5. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
6. Pennsylvania Gov. Rendell: $10 Million Partnership With Harrisburg Venture Capital Firm Boosts PAs Life Sciences Industry
7. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
8. Edwards Lifesciences Reports Strong Fourth Quarter Sales
9. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
10. Advanced Life Sciences to Participate in Antibiotics Expert Panel at the 10th Annual BIO CEO & Investor Conference
11. Caliper Life Sciences Ships 500th IVIS Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... ... 28, 2017 , ... Florida Pain Relief Group, a division ... Cho, MD, has joined its Winter Haven practice. , Dr. Cho’s practice ... techniques to treat and manage many types of pain. , Dr. Cho ...
(Date:5/27/2017)... ... May 26, 2017 , ... A May 8 article ... for colds or respiratory issues that are not responsive to antibiotics nevertheless obtain prescriptions ... may be largely responsible for the problem both in Canada and the United States. ...
(Date:5/27/2017)... ... 2017 , ... In any business, follow up is critical to success. It ... at presenting treatment, there will always be some patients who can’t or won’t make ... best practices when it comes to presenting treatment. After the patient leaves, most ...
(Date:5/27/2017)... Santa Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... show cause for concern, but a new study from the Osteoarthritis Initiative ... vulnerable to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... week to review more than eighty-nine grant submissions all vying for nearly $1,000,000 ... in the Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/8/2017)... May 8, 2017 MACRA replaces the ... fee for service reimbursement. Black Book Research crowdsource-surveyed 8,845 ... 1.       The Market for MIPS Compliance Technology is ... physician practices with 3 or more clinicians seek to ... Q4. "Given the magnitude of the changes, the hunt ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: